US · Healthcare · Biotechnology
EPS came in at 2.22 against a street estimate of 1.34 — a beat of 65.7%.
Analysts rate Ligand Pharmaceuticals Incorporated a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $344.25.
CONFIDENT Ligand closed XOMA acquisition (120+ assets, $2.3B milestones), raised $700M 0% convertible, boosted 2026 EPS guidance. Q2 royalty revenue +32% YoY to $48M; adjusted EPS +48% to $2.37. Portfolio now 40+ commercial products, 70+ clinical stage assets. Q2 2026 No geographic segment breakdown provided; portfolio spans rare disease, oncology, ophthalmology, cardiovascular, autoimmune, neuroscience across diverse partners. Analysts pressed on deal composition post-scale (expect sub-$100M focus), XOMA valuation approach (zero-valued early assets now being reviewed), and cost of capital impact (discipline unchanged, lower cost increases spread). Management reaffirmed sub-$100M strategy, highlighted portfolio management optionality, deferred full 2027 outlook to December Investor Day. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.56% |
| Amvescap Plc. | 6.03% |
| Vanguard Portfolio Management, LLC | 5.71% |
| Jupiter Topco LLC | 5.22% |
| HHG PLC | 5.07% |
| Vanguard Capital Management, LLC | 4.37% |
| State Street Corp | 4.15% |
| FMR Inc | 3.83% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 LIGAND PHARMACEUTICALS INC - FORM 8-K SUMMARY HEADLINE NUMBERS • Ligand Pharmaceuticals entered into a financing agreement with AvenCell Therapeutic | 2026-09-24 |
| Reg FD disclosure · Q3 2026 LIGAND PHARMACEUTICALS INC - FORM 8-K SUMMARY HEADLINE NUMBERS • Ligand acquired royalty and milestone payment rights relating to Santen Pharmaceuti | 2026-09-22 |
| Quarterly report · Q2 2026 LIGAND PHARMACEUTICALS INCORPORATED – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $1,006.7 million at June 30, 2026, up from | 2026-08-07 |
| Results announced · Q3 2026 LIGAND PHARMACEUTICALS Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenue: $63.7 million vs. $47.6 million in Q2 2025 (34% increase) | 2026-08-06 |
| Material agreement · Q3 2026 LIGAND PHARMACEUTICALS - 8-K SUMMARY (July 14, 2026) HEADLINE NUMBERS • Merger completed July 14, 2026: Ligand acquired XOMA Royalty Corporation thr | 2026-07-14 |
| Material agreement · Q2 2026 LIGAND PHARMACEUTICALS INCORPORATED – 8-K SUMMARY HEADLINE NUMBERS • Completed private offering of $700.0 million aggregate principal amount of 0.00 | 2026-06-25 |
| Material agreement · Q2 2026 LIGAND PHARMACEUTICALS INCORPORATED – 8-K SUMMARY HEADLINE NUMBERS • Company issuing $550 million aggregate principal amount of convertible senior n | 2026-06-22 |
| Quarterly report · Q1 2026 LIGAND PHARMACEUTICALS INCORPORATED – Q1 2026 SUMMARY HEADLINE NUMBERS • Cash and short-term investments: $779.4 million as of March 31, 2026 (down | 2026-05-08 |
Readable in the app.
| Announcement | Date |
|---|---|
| Entry into financing agreement with clinical-stage cell therapy company Ligand Pharmaceuticals announced on September 24, 2026 that it entered into a financing agreement with AvenCell Therapeutics, a clinical-stage company developing controllable, allogeneic CAR | 2026-09-24 |
| Acquired royalty and milestone payment rights relating to Ryjunea Ligand Pharmaceuticals announced on September 22, 2026, that it acquired royalty and milestone payment rights related to Santen Pharmaceutical's Ryjunea® from Sydnexis, Inc. for $23 million | 2026-09-22 |
| Company completes merger with HoldCo; shareholders receive cash and contingent value rights On July 14, 2026, XOMA Royalty completed a merger with a holding company (HoldCo). Here's what happened: MERGER TERMS: Each shareholder received $39 per share in cash plus contingent value | 2026-07-14 |
| Entered into merger agreement with XOMA Royalty Corporation Ligand Pharmaceuticals amended its merger agreement with XOMA Royalty Corporation on May 16, 2026. The amendment adds XOMA Royalty Holdings Corporation (HoldCo), a newly formed Nevada holdin | 2026-05-18 |
| Entered into Agreement and Plan of Merger with XOMA Royalty Corporation Ligand Pharmaceuticals agreed to acquire XOMA Royalty Corporation in an all-cash merger deal announced April 27, 2026. XOMA Royalty shareholders will receive $39 per share in cash plus conti | 2026-04-27 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ligand Pharmaceuticals Incorporated — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.